Phase 2 registrational study of SQ3370 in soft tissue sarcoma
Latest Information Update: 11 Oct 2022
At a glance
- Drugs SQ 3370 (Primary)
- Indications Soft tissue sarcoma
- Focus Registrational; Therapeutic Use
- 06 Oct 2022 Status changed from planning to recruiting, according to a Shasqi media release.
- 25 Nov 2021 New trial record
- 11 Nov 2021 According to a Shasqi media release, the company expect to initiate this trial in 2022.